Try our beta test site
3 studies found for:    Lymphoma OR CLL | ALT-803
Show Display Options
Rank Status Study
1 Recruiting QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions: Biological: Rituximab;   Biological: ALT-803
2 Recruiting IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Conditions: Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndromes (MDS);   Lymphoma;   Myeloma;   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML)
Intervention: Biological: ALT-803
3 Not yet recruiting Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloproliferative Syndromes;   Plasma Cell Myeloma;   Colon Carcinoma;   Adenocarcinoma of Rectum;   Soft Tissue Sarcoma;   Ewing's Sarcoma;   Rhabdomyosarcoma
Interventions: Biological: Natural Killer (NK) Cells;   Biological: ALT803

Study has passed its completion date and status has not been verified in more than two years.